IC
SRNE

Ikarian Capital’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Ikarian Capital’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-165,900
Closed -$1.37M – 317
2021
Q1 		$1.37M Buy
+165,900
New +$1.75M 0.05% 225

Other funds holding SRNE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Ikarian Capital's SRNE Position: Q2 2021 in Review

Ikarian Capital sold out of Sorrento Therapeutics, Inc. (SRNE) in Q2 2021, closing a stake of 165,900 shares — an estimated $1.37M sold.

Ikarian Capital first reported a position in SRNE in Q1 2021 and held it in 1 quarter. The position peaked at $1.37M in Q1 2021. 212 funds tracked by Wall St. Rank hold SRNE as of Q2 2021.

  • Ikarian Capital reported no remaining Sorrento Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
  • Ikarian Capital sold 165,900 Sorrento Therapeutics, Inc. shares in Q2 2021, an estimated $1.37M.
  • Ikarian Capital first reported a position in Sorrento Therapeutics, Inc. in Q1 2021 and held it in 1 quarter.
  • Ikarian Capital's Sorrento Therapeutics, Inc. position peaked at $1.37M in Q1 2021.
  • 212 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q2 2021.

Based on Ikarian Capital's 13F filing for Q2 2021, filed 16 Aug 2021.